News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Resolv ER may remedy leading causes of blindness in adults
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Subscribe To Our Newsletter & Stay Updated
